Puma Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
Puma Biotechnology has a total shareholder equity of $71.1M and total debt of $78.1M, which brings its debt-to-equity ratio to 109.8%. Its total assets and total liabilities are $220.7M and $149.6M respectively. Puma Biotechnology's EBIT is $33.0M making its interest coverage ratio 3.7. It has cash and short-term investments of $96.7M.
Key information
109.8%
Debt to equity ratio
US$78.08m
Debt
| Interest coverage ratio | 3.7x |
| Cash | US$96.73m |
| Equity | US$71.09m |
| Total liabilities | US$149.63m |
| Total assets | US$220.72m |
Recent financial health updates
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Recent updates
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price
Jan 14Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Dec 16Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Financial Position Analysis
Short Term Liabilities: PBYI's short term assets ($156.8M) exceed its short term liabilities ($110.4M).
Long Term Liabilities: PBYI's short term assets ($156.8M) exceed its long term liabilities ($39.2M).
Debt to Equity History and Analysis
Debt Level: PBYI has more cash than its total debt.
Reducing Debt: PBYI's debt to equity ratio has reduced from 548.2% to 109.8% over the past 5 years.
Debt Coverage: PBYI's debt is well covered by operating cash flow (43.2%).
Interest Coverage: PBYI's interest payments on its debt are well covered by EBIT (3.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/29 05:51 |
| End of Day Share Price | 2025/01/29 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Puma Biotechnology, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Geoffrey Meacham | BofA Global Research |
| Alethia Young | Cantor Fitzgerald & Co. |